McGregor N R, Dunstan R H, Zerbes M, Butt H L, Roberts T K, Klineberg I J
Collaborative Pain Research Unit, University of Sydney, Westmead Hospital, NSW, Australia.
Biochem Mol Med. 1996 Apr;57(2):73-80. doi: 10.1006/bmme.1996.0012.
Chronic fatigue syndrome (CFS/ME) is a debilitating fatigue illness that has an unknown etiology. We studied 20 chronic fatigue syndrome (CFS) patients, who complied with the Oxford and American CDC definitions, and 45 non-CFS subjects. Participants completed questionnaires, were clinically examined, and had first morning urine specimens collected, which were screened by gas chromatography-mass spectrometry for changes in metabolite excretion. Multivariate analysis of the urinary metabolite profiles differed significantly in the CFS patients compared to the non-CFS patients (P < 0.004). The CFS patients had increases in aminohydroxy-N-methylpyrrolidine (P < 0.00003, referred to as chronic fatigue symptom urinary marker 1, or CFSUM1), tyrosine (P < 0.02), beta-alanine (P < 0.02), aconitic acid (P < 0.05), and succinic acid (P < 0.05) and reductions in an unidentified urinary metabolite, CFSUM2 (P < 0.0007), alanine (P < 0.005), and glutamic acid (P < 0.02). CFSUM1, beta-alanine, and CFSUM2 were found by discriminant function analysis to be the first, second, and third most important metabolites, respectively for discriminating between CFS and non-CFS subjects. The abundances of CFSUM1 and beta-alanine were positively correlated with symptom incidence (P < 0.01 and P < 0.001, respectively), symptom severity, core CFS symptoms, and SCL-90-R somatization (P < 0.00001), suggesting a molecular basis for CFS.
慢性疲劳综合征（CFS/ME）是一种病因不明的使人衰弱的疲劳疾病。我们研究了20名符合牛津和美国疾病控制与预防中心（CDC）定义的慢性疲劳综合征（CFS）患者以及45名非CFS受试者。参与者完成了问卷调查，接受了临床检查，并采集了晨尿样本，通过气相色谱 - 质谱法对其进行筛查以检测代谢物排泄的变化。与非CFS患者相比，CFS患者尿代谢物谱的多变量分析有显著差异（P < 0.004）。CFS患者的氨基羟基 - N - 甲基吡咯烷（P < 0.00003，称为慢性疲劳症状尿标志物1，或CFSUM1）、酪氨酸（P < 0.02）、β - 丙氨酸（P < 0.02）、乌头酸（P < 0.05）和琥珀酸（P < 0.05）增加，而一种未鉴定的尿代谢物CFSUM2（P < 0.0007）、丙氨酸（P < 0.005）和谷氨酸（P < 0.02）减少。通过判别函数分析发现，CFSUM1、β - 丙氨酸和CFSUM2分别是区分CFS和非CFS受试者的最重要的第一、第二和第三代谢物。CFSUM1和β - 丙氨酸的丰度与症状发生率（分别为P < 0.01和P < 0.001）、症状严重程度、CFS核心症状以及SCL - 90 - R躯体化（P < 0.00001）呈正相关，提示CFS存在分子基础。
